The objective of receptivity is to investigate the mechanisms by which external disturbances generate unstable waves. In hypersonic boundary layers, a new receptivity process is revealed, which is that fast and slow a...The objective of receptivity is to investigate the mechanisms by which external disturbances generate unstable waves. In hypersonic boundary layers, a new receptivity process is revealed, which is that fast and slow acoustics through nonlinear interaction can excite the second mode near the lower-branch of the second mode. They can generate a sum-frequency disturbance though nonlinear interaction,which can excite the second mode. This receptivity process is generated by the nonlinear interaction and the nonparallel nature of the boundary layer. The receptivity coefficient is sensitive to the wavenumber difference between the sumfrequency disturbance and the lower-branch second mode.When the wavenumber difference is zero, the receptivity coefficient is maximum. The receptivity coefficient decreases with the increase of the wavenumber difference. It is also found that the evolution of the sum-frequency disturbance grows linearly in the beginning. It indicates that the forced term generated by the sum-frequency disturbance resonates with the second mode.展开更多
AIM To evaluate the safety and efficacy of sorafenib plus transarterial chemoembolization(TACE) treatment for intermediate hepatocellular carcinoma(HCC).METHODS Sixty-seven patients with intermediate-stage [Barcelona ...AIM To evaluate the safety and efficacy of sorafenib plus transarterial chemoembolization(TACE) treatment for intermediate hepatocellular carcinoma(HCC).METHODS Sixty-seven patients with intermediate-stage [Barcelona Clinic liver cancer stage B(BCLC-B)] HCC who were treated with sorafenib plus TACE or TACE alone between 2009 and 2011 were included in the study. Follow-up was until 2014 or patient death. Two groups were defined in the experiment: The experimental group, treated with sorafenib plus TACE, and the control group, treated with standard TACE alone.RESULTS The Kaplan-Meier survival analysis showed that the median overall survival(m OS) of the experimental group was 35.2 mo, while that of the control group was 22.0 mo(P < 0.05). Sorafenib plus TACE showed higher incidence rates of rash, hand-foot syndrome(HFS), and hypertension(P < 0.05) than TACE treatment alone.CONCLUSION Sorafenib plus TACE treatment for BCLC-B HCC significantly prolonged the m OS of patients compared to TACE treatment alone. The most common toxicities with sorafenib were rash(31.6%), HFS(39.5%) and hypertension(31.6%), but there were no intolerable adverse events. The Cox multivariate analysis showed that the survival of patients with BCLC-B HCC depended on the Child-Pugh classification, tumor diameter, and treatment with sorafenib plus TACE compared to TACE alone.展开更多
基金supported by the National Natural Science Foundation of China (Grants 11332007 and 11202147)the Specialized Research Fund for the Doctoral Program of Higher Education (Grants 20120032120007)
文摘The objective of receptivity is to investigate the mechanisms by which external disturbances generate unstable waves. In hypersonic boundary layers, a new receptivity process is revealed, which is that fast and slow acoustics through nonlinear interaction can excite the second mode near the lower-branch of the second mode. They can generate a sum-frequency disturbance though nonlinear interaction,which can excite the second mode. This receptivity process is generated by the nonlinear interaction and the nonparallel nature of the boundary layer. The receptivity coefficient is sensitive to the wavenumber difference between the sumfrequency disturbance and the lower-branch second mode.When the wavenumber difference is zero, the receptivity coefficient is maximum. The receptivity coefficient decreases with the increase of the wavenumber difference. It is also found that the evolution of the sum-frequency disturbance grows linearly in the beginning. It indicates that the forced term generated by the sum-frequency disturbance resonates with the second mode.
基金National Natural Science Foundation of China,No.81360360 and No.81660399Yunnan Provincial Engineering Research Center of Major Surgical Diseases(2014)+5 种基金Innovation Research Team Project of Yunnan Institutions of Higher Education(2014)Innovation Research Team Project of Yunnan Province,No.2015HC033Yunnan Provincial Academician Workstation of Xiaoping Chen(2016)Breeding Program for Major Scientific and Technological Research Achievements of Kunming Medical University,No.CGPY201607the Medical Leading Talent Project of Yunnan Province(to Wang L)No.L201622
文摘AIM To evaluate the safety and efficacy of sorafenib plus transarterial chemoembolization(TACE) treatment for intermediate hepatocellular carcinoma(HCC).METHODS Sixty-seven patients with intermediate-stage [Barcelona Clinic liver cancer stage B(BCLC-B)] HCC who were treated with sorafenib plus TACE or TACE alone between 2009 and 2011 were included in the study. Follow-up was until 2014 or patient death. Two groups were defined in the experiment: The experimental group, treated with sorafenib plus TACE, and the control group, treated with standard TACE alone.RESULTS The Kaplan-Meier survival analysis showed that the median overall survival(m OS) of the experimental group was 35.2 mo, while that of the control group was 22.0 mo(P < 0.05). Sorafenib plus TACE showed higher incidence rates of rash, hand-foot syndrome(HFS), and hypertension(P < 0.05) than TACE treatment alone.CONCLUSION Sorafenib plus TACE treatment for BCLC-B HCC significantly prolonged the m OS of patients compared to TACE treatment alone. The most common toxicities with sorafenib were rash(31.6%), HFS(39.5%) and hypertension(31.6%), but there were no intolerable adverse events. The Cox multivariate analysis showed that the survival of patients with BCLC-B HCC depended on the Child-Pugh classification, tumor diameter, and treatment with sorafenib plus TACE compared to TACE alone.
基金The study was funded by the National Natural Science Foundation of Hebei （No.H2018201179）. Hebei University of Science and Technology （No. QN2016077）. Health and Family Planning Commission of Hebei （No. 20160388）.
